Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03439527
Other study ID # H2020-SC1-2016-2017
Secondary ID 731377
Status Completed
Phase Phase 1
First received
Last updated
Start date January 22, 2020
Est. completion date October 21, 2021

Study information

Verified date October 2021
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The rising success of cell therapies places an increasing burden on health care costs. Consequently, the need to reduce production costs while maintaining quality has been widely acknowledged. In addition, the demand for high-quality products with an optimal safety profile is increasing. The proposed cell treatment is the first therapeutical option with the possibility to revert the underlying condition. The investigators expect that this healing response will be achieved with minimal side effects justifying the addional costs and complexity.


Description:

muscle precursor cells (MPCs) will be isolated from biopsies of the lower leg of patients, seeded, expanded and cultivated in vitro in a GMP facility to generate vital muscle cells dedicated for implantation. These muscle cells exhibit myogenic phenotype (IHC and flow cytometry) and therefore morphological and histological prerequisites approximating the properties of native skeletal muscle tissue. The muscle progenitor cells shall be applied in external sphincter muscle for the treatment of patients with stress urinary incontinence.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date October 21, 2021
Est. primary completion date September 3, 2021
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: Adult women 20y-60y - Incontinence >/= grade I since at least 6 months - Predominant clinical diagnosis of SUI - Candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons). - Post void residual volume of <100 ml (exclusion of overflow incontinence) - Can independently use toilet without difficulty - Capacity to answer the questionnaires of evaluation - Negative blood test for: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C Anti-HCV-Ab, Syphilis - Competent to comprehend, sign and date informed consent form before any study-specific procedure is performed Exclusion Criteria: - History of anti-incontinence or prolapse surgery. - Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract: - Clinically significant cystocele or rectocele - Ureteric bladder, urethral or rectal fistula - Uncorrected congenital abnormality leading to urinary incontinence - Interstitial cystitis - Urinary urgency that results in leakage (as a predominant symptom) - Adult enuresis - Urodynamically proven detrusor instability - Sensory urgency defined as first sensation of bladder fill (urge to void) of <100 ml; bladder capacity of <300 ml - No sensation at any time during the simple filling cystometry procedure - Known urethral stenosis (ureterocystoscopy) or urethral diverticulum - History of urogenital cancer or history of pelvic radiotherapy - Women who are pregnant, breast feeding or <12 months postpartum Note: Female subjects who are surgically sterilized, hysterectomized or post-menopausal for longer than 2 years are not considered as having child bearing potential. No pregnancy test will be performed for this population. - Untreated symptomatic urinary tract infection - Fever (as defined by = 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days - Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment - Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results. - Known allergy or intolerance of at least one of the active ingredients or excipients of the investigational products - Known allergy or intolerance of Penicillin or Streptomycin - Known genetically determined or acquired muscular disease. - Known Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism). - Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study. - Chronic use of any of the following drugs and not stopped for at least 2 weeks prior to inclusion into the study: selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs. - Chronic use of any of the following drugs and not stopped for at least 6 months prior to inclusion into the study: Antidepressants or neuroleptic drugs.

Study Design


Intervention

Other:
Muscle Precursor Cells (MPCs), ATMP
The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.

Locations

Country Name City State
Switzerland University Hospital Zurich Zürich

Sponsors (3)

Lead Sponsor Collaborator
University of Zurich Salzburger Landeskliniken, University Hospital Tuebingen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of clinically relevant Adverse Events of MPCs or related to cell injection Number of clinically relevant findings related to cell injection at 3 months post-implantation
Secondary Feasibility of MPC injection Percentage of subjects with successful injection day of implantation
Secondary Efficacy of MPC injection measured by post-void residual volume post-void residual volume at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation
Secondary Efficacy of MPC injection measured by Uroflowmetry Uroflowmetry: urinary flow pattern at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation
Secondary Efficacy of MPC injection measured by Urodynamic Evaluation 2 Filling-Cystometries at baseline, 3 months and 6 months post-implantation
Secondary Efficacy of MPC injection measured by Urodynamic Evaluation 2 Pressure-Flow studies at baseline, 3 months and 6 months post-implantation
Secondary Efficacy of MPC injection measured by Urodynamic Evaluation Urethal-Pressure-Profile at baseline, 3 months and 6 months post-implantation
Secondary Efficacy of MPC injection measured by 1h pad test 1h pad test at baseline, 1 month, 3 months and 6 months post-implantation
Secondary Efficacy measured by average Incontinence Score Incontinence Score. Range from 0 (no incentinence) to 21 (highly incontinent) at baseline, 1 month, 3 months and 6 months post-implantation
Secondary Efficacy measured by average score of Visual Analog Scale of degree of suffering Visual Analog Scale of degree of suffering. Range 0 (worst) to 10 (best) at baseline, 1 month, 3 months and 6 months post-implantation
Secondary Efficacy measured by average score of Quality of Life Quality of Life Score, using SF-36v2™ Health Survey at baseline, 1 month, 3 months and 6 months post-implantation
Secondary Efficacy Number for (planned) subsequent incontinence surgery 6 months post-implantation
Secondary Number of patients with abnormal laboratory values and/or Adverse Events that are related to MPC injection Safety measures (ultrasound, physical examination, laboratroy) at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02867748 - TVT-ABBREVO Versus SERASIS for the Treatment of Female Urinary Stress Incontinence: 1 Year Outcomes of a Comparative Study With 2 Trans-obturator Sub Mid Urethral Slings N/A
Recruiting NCT02617797 - Radiofrequency in the Female Stress Urinary Incontinence N/A
Active, not recruiting NCT02538991 - TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence N/A
Completed NCT02480231 - Mid-Urethral Sling Tensioning Trial N/A
Terminated NCT02591381 - Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00190567 - Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence Phase 2
Completed NCT02423486 - The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback N/A
Completed NCT01754558 - One Year Outcome Using the Ajust System for Treatment of Urinary Stress Incontinence N/A
Recruiting NCT00136071 - Transvaginal Tension Free Vaginal Tape-Obturator (TVT-O) Versus Transobturator Tape-Mentor (TOT) in the Management of Urodynamic Stress Urinary Incontinence N/A
Completed NCT00190619 - Efficacy and Safety of Duloxetine Phase 3
Completed NCT04288648 - Pelvic Floor Contraction in Different Positions Among Women With and Without Stress Urinary Incontinence
Active, not recruiting NCT05182632 - Tele-rehabilitation Group Program for Urinary Incontinence in Older Women N/A
Completed NCT03672461 - A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women N/A
Completed NCT02407145 - Safety and Efficacy of PVDF (DynaMesh®-SIS Soft) Retropubic Midurethral Slings in Stress Urinary Incontinence in Women
Completed NCT01784172 - Efficacy and Safety Study of Electroacupuncture for Simple Female Stress Urinary incontinence-a Multicenter Trial Phase 2
Not yet recruiting NCT06469320 - Urinary Incontinence and Other Pelvic Floor Dysfunctions in Trail Runners
Recruiting NCT02935803 - A Study on the Anti-incontinent Effectiveness of the mTVM Method in POPQ Stage II-III Patients N/A
Active, not recruiting NCT02039830 - Group Versus Individual Physiotherapy for Urinary Incontinence in Aging Women N/A
Recruiting NCT04817839 - Optimal Duration of Post-Operative Activity Restriction After Midurethral Sling Procedures N/A